Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy

PURPOSE: Current first-line chemotherapy for patients with metastatic adrenocortical cancer (ACC) includes doxorubicin, etoposide, cisplatin, and mitotane with a reported response rate of only 23.2%. New therapeutic leads for patients with refractory tumors are needed; there is no standard second-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Millis, Sherri Z., Ejadi, Samuel, Demeure, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686344/
https://www.ncbi.nlm.nih.gov/pubmed/26715866
http://dx.doi.org/10.4137/BIC.S34292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686344/
https://www.ncbi.nlm.nih.gov/pubmed/26715866
http://dx.doi.org/10.4137/BIC.S34292

Ejemplares similares